The U.S. Food and Drug Administration (FDA) has rejected three attempts by Johnson & Johnson to expand the approval of its anti-blood clotting drug, Xarelto, according to a report in the Wall Street Journal. Xarelto is approved as a preventative medicine for patients with pulmonary…
On Friday, February 20, 2015, DePuy/ Johnson & Johnson agreed to pay approximately $420 million more to resolve approximately 1400 additional DePuy ASR lawsuits. The order came from the Court extending the settlement offer to Plaintiffs who had revision surgery after August 31, 2013 up…
On December 22, 2014, China officially approved imports of a type of genetically modified corn – Syngenta’s Agrisure Viptera® MR162, ending China’s yearlong ban of imports of all corn containing any trace of the Viptera MR162 trait. The ban had essentially shut U.S. corn out…
Just over two years since the Stryker Rejuvenate and ABGII hip implant products were recalled from the market in June 2012, national leadership in the multi-district litigation (MDL) today announced a global settlement proposal for all Stryker Rejuvenate and ABGII hip implant victims who have…
Nearly 3,000 lawsuits have been filed against Stryker related to their Rejuvenate and ABG II Modular-Neck Stem Hip Implants. Here are some common questions that patients and the general public may have regarding these products: 1) Why were the Stryker Rejuvenate and ABG II Modular-Neck…
